Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolytics Biotech has received Canadian patent entitled 'Reovirus for the treatment of neoplasia'. The claims describe using various human reoviruses to treat cancers that have inactivated or deleted PKR, a host cellular protein responsible for preventing virus replication within a cell.
Subscribe to our email newsletter
Matt Coffey, chief scientific officer of Oncolytics, said: “This is a broad patent that expands our coverage in Canada in the area of cancers with inactivated PKR.”